In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.

Animal / preclinicalThe Journal of antimicrobial chemotherapy· Jul 2026

In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.

Inès Fenniri, Paulo J M Bispo, Camille Andre

Read paper

OphthalmologyAnimal / preclinicalQ1IF 3.7

Telavancin 25 mg/mL eye drops caused less eye irritation than vancomycin in mice.

In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.

Inès Fenniri … Camille Andre

The Journal of antimicrobial chemotherapy · Jul 2026

Background

MRSA is associated with poor visual outcomes despite treatment with topical fortified vancomycin (25-50 mg/mL), the current standard of care.

Purpose

To compare the in vivo ocular tolerability of topical telavancin and vancomycin at 25 and 50 mg/mL in a murine maximum-tolerated-dose model.

Methods

Immunocompetent female BALB/c mice (n = 24; six groups, four/group) received 20 instillations, 15 min apart over 5 h, of telavancin or vancomycin (25 or 50 mg/mL) or matching vehicles [250 or 500 mg/mL hydroxy-propyl-β-cyclodextrin (HPβCD) for telavancin; 0.9% NaCl for vancomycin].

n = 24

1/4

Results

1/4

eyes checked for redness, swelling, discharge - less damage than vancomycin

n = 24

More results

Vancomycin showed dose-dependent toxicity.

“

Conclusion

The telavancin 25 mg/mL formulation was better tolerated than the fortified vancomycin formulation tested in this model. These findings support further preclinical evaluation for MDR Gram-positive ocular infections.

In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.

In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model.

Related papers